Business Wire

SOSAFE

4.6.2024 09:01:35 CEST | Business Wire | Press release

Share
SoSafe Appoints Dropbox Senior Executive Laura Ryan as Chief People Officer

SoSafe, Europe’s largest security awareness and human risk management vendor, has appointed seasoned HR executive Laura Ryan as Chief People Officer to support the organisation as they continue to scale operations internationally in the face of rising global cyber security threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604322632/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Laura Ryan appointed as new Chief People Officer at largest security awareness and human risk management platform SoSafe. (Photo: Business Wire)

Laura will lead SoSafe’s people function, overseeing the development of a best-in-class team to help deliver the company’s next chapter of strategic growth. She will manage human resources, people and talent, workspace and community, and operations, acting as an engine to accelerate the company’s mission and long-term vision to strengthen digital self-defence.

With over 20 years of hands-on experience in the technology and financial services industries, Laura has actively supported the evolution of HR functions. Prior to joining SoSafe, she worked almost nine years at Dropbox, most recently as Vice President Global HR Business Partnering. Prior to this, Laura spent over five years at Google and over seven years in Financial Services in a number of HR roles, honing her HR craft.

Laura Ryan, incoming Chief People Officer at SoSafe: “Throughout my career I've been passionate about scaling organisations, helping companies achieve this by fostering innovation and creating workplaces that inspire people to do their best work. SoSafe is working in an extremely interesting market with very strong dynamics: Cybercrime is the biggest threat to organisations and SoSafe delivers a human-centric solution based on psychology. This gives the company and the team a very strong purpose and I am very excited to contribute to their mission to empower people facing digital threats.”

SoSafe is currently leading the category evolution from security awareness and training to human risk management through product innovation, accelerating its sustainable growth. Since the beginning of 2022, they have grown from 180 employees in Cologne, Germany, to 500 employees across nine locations in Europe with around 100 open positions, recently adding two additional office hubs in Dublin, Ireland, and Chemnitz, Germany.

Dr Niklas Hellemann, CEO of SoSafe: "One of the pillars of our success is the excellence of our people - we are proud to have an outstanding team to drive our ambitious plans. Laura brings a wealth of experience in fast-paced, multi-cultural organisations and has proven her ability to build and lead people divisions in high growth technology companies. I am very excited to have her join our management team and look forward to working with her to drive further growth for the business.”

Laura's appointment follows a series of senior hires to strengthen the company's expertise.:

  • Megan Brown joins as Vice President of Global Partnerships, bringing more than 15 years of sales experience at LogicGate, Checkster and CareerBuilder to lead SoSafe's plans to expand its channel sales through international partnerships.
  • Gina Dragulin joins as Vice President of Product Marketing to ensure that SoSafe's product innovations are brought to life and their customers get highest value. Prior to joining SoSafe, she worked for Miro, Microsoft and other tech companies while leading various marketing functions.
  • Thomas Owen joins as Chief Information Security Officer, bringing with him a wealth of experience in the security industry from companies such as Grafana Labs, iloomi and Snyk.

About SoSafe

SoSafe, founded by a team of behavioural scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioural science, SoSafe enhances secure behaviour across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defence by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 500 employees in nice locations: Cologne (headquarters), Amsterdam, Berlin, Chemnitz, Dublin, London, Paris, Lisbon, and Munich.

Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604322632/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye